CEO sold ~$1.43M of HALO shares in the open market

Past results only. Not a forecast.

Record ID

0001159036-26-000119

Filed / recorded

Sep 12, 2026, 12:35 AM UTC

Added to OQRO

Oct 6, 2026, 7:59 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

HALOZYME THERAPEUTICS, INC.

Issuer CIK

1159036

Ticker

HALO

Reporting person

Helen Torley

Relationship

Director, Officer

Officer title

PRESIDENT AND CEO

Security

Common Stock

Table

Non-derivative (Table I)

Transaction date

Sep 9, 2026

Transaction code

S

Shares / units

13,304

Price per share

$107.22

Acquired / disposed

Disposed (D)

Shares owned after

774,476

Ownership form

Direct

Amendment

No

1. The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028.
2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.640 to $107.632. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.